Finally, we have demonstrated pre-clinical efficacy of the BCL2 inhibitor, ABT-737, both in an in vitro setting and using an in vivo model of human BCR-ABL-positive ALL. The gene discussed is ABL1; the disease is acute lymphoblastic leukemia.